PMID: 42061370

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

Wander Seth A, Lloyd Maxwell R, Keenan Jennifer C, Scott Elizabeth C, Niemierko Andrzej, Spring Laura M, Fell Geoffrey G, Shin Jennifer, Isakoff Steven J, Moy Beverly

The Lancet. Oncology · 2026

Vol. 27, Issue 5, pp. 580-591

This entry links to third-party literature. For research use only.